Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33197449.
- Also identified by DOI 10.1053/j.gastro.2020.10.046 and PMC identifier 7878333.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The increasing incidence of primary and recurring Clostridioides difficile infections (CDI), which evade current treatment strategies, reflects the changing biology of C difficile. Here, we describe a putative plasmid-mediated mechanism potentially driving decreased sensitivity of C difficile to vancomycin treatment. We identified a broad host range transferable plasmid in a C difficile strain associated with lack of adequate response to vancomycin treatment. The transfer of this plasmid to a vancomycin-susceptible C difficile isolate decreased its susceptibility to vancomycin in vitro and resulted in more severe disease in a humanized mouse model. Our findings suggest plasmid acquisition in the gastrointestinal tract to be a possible mechanism underlying vancomycin treatment failure in patients with CDI, but further work is needed to characterize the mechanism by which plasmid genes determine vancomycin susceptibility in C difficile.
Medical subject headings
- Anti-Bacterial Agents
- Clostridioides difficile
- Clostridium Infections
- Plasmids
- Vancomycin